Outbreaks of severe virus infections with the potential to cause global pandemics are
increasing. In many instances these outbreaks have been newly emerging (SARS …

Abstract The Asian-Pacific Association for the Study of the Liver (APASL) convened an
international working party on the “APASL consensus statements and recommendation on …

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide. The long-term impact of HCV infection is highly variable, from minimal changes …

Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …

Background Treatment for chronic hepatitis C (CH‐C) is rapidly changing and moving away
from an interferon and ribavirin‐based therapy to interferon‐free ribavirin‐free all oral …

BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)-28B gene on
chromosome 19 have been associated with peginterferon-alfa–induced clearance of …

Treatment predictors are important tools for the management of therapy in patients with
chronic hepatitis B and C virus (HBV, HCV) infection. In chronic hepatitis B, several …

The current preferred treatment for patients with hepatitis C virus (HCV) is combination
therapy consisting of pegylated interferon alfa and ribavirin (RBV) for 24–48 weeks …

Abstract The Asian Pacific Association for the Study of the Liver (APASL) convened an
international working party on the “APASL Consensus Statements and Management …

Background & Aims On-going risk behaviour can lead to hepatitis C virus (HCV) reinfection
following successful treatment. We aimed to assess the incidence of persistent HCV …